The historical rank and industry rank for Regeneron Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:
REGN'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.66 Med: 57.48 Max: 4276.4
Current: 23.66
During the past years, Regeneron Pharmaceuticals's highest Shiller PE Ratio was 4276.40. The lowest was 23.66. And the median was 57.48.
REGN's Shiller PE Ratio is ranked better than 72.46% of 138
companies
in the Biotechnology industry
Industry Median: 37.16
vs REGN: 23.66
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Regeneron Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was $11.540. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $30.90 for the trailing ten years ended in Sep. 2024.
Shiller PE for Stocks: The True Measure of Stock Valuation
Regeneron Pharmaceuticals Shiller PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Regeneron Pharmaceuticals's Shiller PE Ratio
For the Biotechnology subindustry, Regeneron Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's Shiller PE Ratio falls into.
Regeneron Pharmaceuticals Shiller PE Ratio Calculation
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Regeneron Pharmaceuticals (NAS:REGN) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Regeneron Pharmaceuticals Shiller PE Ratio Related Terms
Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
REGN has been successfully added to your 